Citius Oncology Valuation
| CTOR Stock | 1.13 0.02 1.80% |
Today, the firm appears to be undervalued. Citius Oncology shows a prevailing Real Value of USD2.31 per share. The current price of the firm is USD1.13. Our model approximates the value of Citius Oncology from analyzing the firm fundamentals such as Return On Equity of -0.54, current valuation of 95.21 M, and Shares Owned By Insiders of 83.88 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Citius Oncology's valuation include:
Undervalued
Today
Please note that Citius Oncology's price fluctuation is dangerous at this time. Calculation of the real value of Citius Oncology is based on 3 months time horizon. Increasing Citius Oncology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Citius stock is determined by what a typical buyer is willing to pay for full or partial control of Citius Oncology. Since Citius Oncology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Citius Stock. However, Citius Oncology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.13 | Real 2.31 | Target 6.0 | Hype 1.1 | Naive 1.1 |
The intrinsic value of Citius Oncology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Citius Oncology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Citius Oncology helps investors to forecast how Citius stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Citius Oncology more accurately as focusing exclusively on Citius Oncology's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Citius Oncology's intrinsic value based on its ongoing forecasts of Citius Oncology's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Citius Oncology's closest peers.
Citius Oncology Cash |
|
Citius Oncology Total Value Analysis
Citius Oncology is currently estimated to have valuation of 95.21 M with market capitalization of 101.52 M, debt of 3.8 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Citius Oncology fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
95.21 M | 101.52 M | 3.8 M |
Citius Oncology Asset Utilization
One of the ways to look at asset utilization of Citius is to check how much profit was generated for every dollar of assets it reports. Citius Oncology shows a negative utilization of assets of -0.16 percent, losing USD0.001587 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Citius Oncology shows how discouraging it operates for each dollar spent on its assets.Citius Oncology Profitability Analysis
Based on the key profitability measurements obtained from Citius Oncology's financial statements, Citius Oncology may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess Citius Oncology's ability to earn profits and add value for shareholders.Net Loss | First Reported 2010-12-31 | Previous Quarter -22.3 M | Current Value -21.2 M | Quarterly Volatility 9.7 M |
For Citius Oncology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Citius Oncology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Citius Oncology utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Citius Oncology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Citius Oncology over time as well as its relative position and ranking within its peers.
Citius Oncology Earnings per Share Projection vs Actual
By analyzing Citius Oncology's earnings estimates, investors can diagnose different trends across Citius Oncology's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Citius Oncology is based on EPS before non-recurring items and includes expenses related to employee stock options.Citius Oncology Ownership Allocation
Citius Oncology holds a total of 88.28 Million outstanding shares. Citius Oncology shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 83.88 percent of Citius Oncology outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Citius Oncology Profitability Analysis
Net Loss for the year was (24.76 M) with profit before overhead, payroll, taxes, and interest of 0.About Citius Oncology Valuation
The stock valuation mechanism determines Citius Oncology's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Citius Oncology based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Citius Oncology. We calculate exposure to Citius Oncology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Citius Oncology's related companies.Citius Oncology Growth Indicators
Investing in growth stocks can be very risky. If the company such as Citius Oncology does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 73.3 M | |
| Forward Price Earnings | 35.5872 |
Citius Oncology Current Valuation Indicators
Citius Oncology's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Citius Oncology's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Citius Oncology, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Citius Oncology's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Citius Oncology's worth.Additional Tools for Citius Stock Analysis
When running Citius Oncology's price analysis, check to measure Citius Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology is operating at the current time. Most of Citius Oncology's value examination focuses on studying past and present price action to predict the probability of Citius Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology's price. Additionally, you may evaluate how the addition of Citius Oncology to your portfolios can decrease your overall portfolio volatility.